SCHEMBL1649263

SCHEMBL1649263

CC(COc1c(-c2ccoc2)ccc(CS(=O)(=O)c2ccccc2)c1C(=O)O)NC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.37
NPSR1 Q6W5P4 5/20 0.36
LMNA P02545 4/20 0.36
XBP1 P17861 4/20 0.36
HTT P42858 4/20 0.36
HPGD P15428 3/20 0.36
PKM P14618 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
JAK2 O60674 2/20 0.36
S1PR4 O95977 2/20 0.36
ALOX15 P16050 2/20 0.36
TP53 P04637 2/20 0.36
MAPK1 P28482 2/20 0.36
S1PR1 P21453 1/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
MMP13 P45452 2/20 0.35
ALDH1A1 P00352 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1648453 0.94 NPSR1 (0.36) METAP2NPSR1LMNAXBP1HTT
SCHEMBL18801133 0.89 METAP2 (0.36) METAP2MMP13NAT1
SCHEMBL1648412 0.85 CA1 (0.40) METAP2NPSR1XBP1HTTHPGD
SCHEMBL1649052 0.85 CA1 (0.41) METAP2NPSR1XBP1HTTHPGD
SCHEMBL1648491 0.85 METAP2 (0.36) METAP2MMP13NAT1
SCHEMBL18801134 0.85 KMT2A (0.37) METAP2NPSR1LMNAHSD17B10MEN1
SCHEMBL6844906 0.84 METAP2 (0.40) METAP2LMNANAT1TSHR
Hydrochloric Acid SCHEMBL1648036 0.83 METAP2 (0.39) METAP2LMNANAT1TSHR
SCHEMBL1649265 0.81 METAP2 (0.34) METAP2NAT1
SCHEMBL1648269 0.81 METAP2 (0.43) METAP2MEN1KMT2AMAPTNAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
EP-2486004-B1 SULPHONE COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY ZAFGEN INC (US) 2017-05-03 EP disclosed
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN INC (US) 2016-02-25 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-9067905-B2 Sulphone compounds and methods of making and using same ZAFGEN, INC. (US) 2015-06-30 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same ZAFGEN, INC. 2013-02-28 US disclosed
EP-2486004-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME Zafgen Corporation (US) 2012-08-15 EP disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed
WO-2011044506-A2 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN CORPORATION (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051531-A1 SULPHONE COMPOUNDS AND METHODS OF MAKING AND USING SAME METAP2, DNPEP, STS METAP2 1/4885NPSR1 1100/4885LMNA 4621/4885
US-20130053364-A1 Sulphone Compounds and Methods of Making and Using Same METAP2, DNPEP, STS METAP2 1/4885NPSR1 1100/4885LMNA 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.